Search through
The global ophthalmic sector is currently witnessing a transformative shift in the management of intraocular pressure, with Dorzolamide Hydrochloride (CAS No: 130693-82-2) positioned as a fundamental carbonic anhydrase inhibitor for treating open-angle glaucoma and ocular hypertension. Market intelligence indicates a significant pivot towards advanced drug delivery systems, such as cyclodextrin complexation and nanoliposome formulations, which address the traditional limitations of short half-life and frequent dosing schedules to improve patient adherence. Furthermore, the integration of Dorzolamide Hydrochloride into the broader ophthalmology small molecule API market, valued at USD 4.88 billion in 2024, is being propelled by increased CDMO collaborations and a strategic focus on localized, high-purity API production to mitigate global supply chain disruptions. We are an established Dorzolamide Hydrochloride API supplier with >= 99% purity globally for semi-finished formulators, providing comprehensive analytical (HPLC/NMR/MS) and supporting Dorzolamide Hydrochloride COA/TDS/SDS region-specific regulatory support, reliable lead times, and worldwide supply chain capabilities.
The global ophthalmic sector is currently witnessing a transformative shift in the management of intraocular pressure, with Dorzolamide Hydrochloride (CAS No: 130693-82-2) positioned as a fundamental carbonic anhydrase inhibitor for treating open-angle glaucoma and ocular hypertension. Market intelligence indicates a significant pivot towards advanced drug delivery systems, such as cyclodextrin complexation and nanoliposome formulations, which address the traditional limitations of short half-life and frequent dosing schedules to improve patient adherence. Furthermore, the integration of Dorzolamide Hydrochloride into the broader ophthalmology small molecule API market, valued at USD 4.88 bi...
Chemical Properties & Specifications
P260, P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P314, P330, and P501
Acute Tox. 4
Skin Irrit. 2
A topical carbonic anhydrase inhibitor used in ophthalmic solutions to treat elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension
A highly specific inhibitor of carbonic anhydrase II that reduces the production of aqueous humor to preserve optic nerve health and prevent vision loss
A biochemical agent utilized in clinical and pharmacological studies to investigate the role of isoenzyme-specific inhibition in ocular fluid dynamics.
Dorzolamide Hydrochloride is a potent carbonic anhydrase II inhibitor used primarily in ophthalmic solutions to treat increased intraocular pressure caused by open-angle glaucoma or ocular hypertension
This compound is primarily used in the pharmaceutical and healthcare industries for the production of ophthalmic medications and treatments for eye diseases
It is typically formulated as a 2% ophthalmic solution (eye drops) and is compatible with aqueous vehicles, often used in combination with other agents like timolol maleate
Standard specifications include CAS number 130693-82-2, high purity (typically ≥98% or ≥99%), and available documentation such as COA, TDS, impurity reports, and regulatory compliance documents
Scimplify has capabilities for global distribution and custom synthesis through an integrated network of manufacturers and logistics partners with reliable lead time
The product is export ready with a standard MOQ starting from 100 kgs, with lead times for international customers depending on the shipping destination and specific grade.
Category : Pharmaceutical Actives & Precursors
Sub-Category : Active Pharmaceutical Ingredients (APIs)
Description : Calcium acetate monohydrate (CAS No: 5743-26-0) occupies a critical position in the global specialit...
Category : Pharmaceutical Actives & Precursors
Sub-Category : Intermediates & Precursors
Description : P-Nitrobenzoyl Chloride (CAS 122-04-3) is a critical building block in the API intermediates market,...
